Prognostic Significance of Molecular Markers and Targeted Regimens in the Management of Acute Myeloid Leukemia
This information was originally presented at the NCCN 23rd Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care held in Orlando, Florida, from March 22 - 24, 2018.
Category
  • Acute Myelogenous Leukemia
Format
  • Recorded Webcast
Credits
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Consideration for Use of Novel Agents in Acute Myeloid Leukemia
There is a need for improved therapeutic strategies to combat AML disease progression.  Recent developments have expanded treatment options for acute myeloid leukemia (AML) including targeted agents, antibody-drug conjugates and novel formulations.
Category
  • Acute Myelogenous Leukemia
Format
  • Recorded Webcast
Credits
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation